(RTTNews) - Vaxcyte, Inc. (PCVX), a clinical-stage vaccine innovation company, announced late Tuesday the pricing of public offerings of common stock, pre-funded warrants and convertible senior notes for total proceeds of approximately $1.0 billion.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.